National Action Plan For The MHPSS Response To COVID-19

National Action Plan for the MHPSS Response to COVID-19

This action plan was developed as part of the national response to the COVID-19 outbreak. It aims at comprehensively addressing the MHPSS aspects of the COVID-19 outbreak in Lebanon for all persons living in the country. It was developed by the MOPH-National Mental Health Programme (NMHP) with WHO and UNICEF, in line with the IASC Briefing note on addressing mental health and psychosocial aspects of COVID-19 Outbreak- version 1.0 and the local needs, health system and national mental health strategy.

Goals:

Promote mental health and mitigate COVID-19 related stressors including stigma and discrimination against persons affected and health workers.
Provide mental health support to the persons in quarantine in the hospital or at home and their families.
Support the mental health of health workers and first responders in the response.
Ensure continuity of mental health care for persons using mental health services in line with IPC guidelines.

To view the action plan, click here: National Action Plan for MHPSS Response to COVID-19

...

190

All

ATC	Name	B/G	Ingredients	Dosage	Form	Price
C09CA03	DIOVAN	B	Valsartan - 160mg	160mg	Tablet, film coated	846,621 L.L
D07XC01	LOTRIDERM	B	Betamethasone (dipropionate) - 0.5mg/g, Clotrimazole - 10mg/g		Cream	470,345 L.L
N05AX13	TREVICTA	B	Paliperidone - 175mg	175mg	Injectable suspension, prolonged release	35,006,953 L.L
R05D	DULSANA WITH CODEINE	B	Menthol - 0.25mg/5ml, Ammonium chloride - 100mg/5ml, Codeine phosphate - 10mg/5ml, Ephedrine HCl - 4mg/5ml, Carbinoxamine maleate - 2mg/5ml		Syrup	273,888 L.L
S02DA01	OTIPAX	B	Lidocaine HCl - 1g/100g, Phenazone - 4g/100g		Drops	236,516 L.L
C03CA01	LASIX	B	Furosemide - 500mg	500mg	Tablet	1,454,038 L.L
G04BE08	CIALIS	B	Tadalafil - 20mg	20mg	Tablet, film coated	3,101,588 L.L
N01AB07	SUPRANE (DESFLURANE, USP)	B	Desflurane -		Inhalation	9,371,654 L.L
N03AG01	DEPAKINE	B	Sodium Valproate - 200mg/ml	200mg/ml	Solution	360,150 L.L
N05AX13	TREVICTA	B	Paliperidone - 263mg	263mg	Injectable suspension, prolonged release	40,713,332 L.L
S02DC	WAXSOL	B	Docusate sodium - 0.5%	0.5%	Drops solution	157,230 L.L
A07EC02	SALOFALK	B	Mesalazine - 1000mg	1000mg	Granules, gastro-resistant, prolonged release	3,874,298 L.L
C03CA02	BURINEX	B	Bumetanide - 1mg	1mg	Tablet	335,961 L.L
D07XC01	DIPROSALIC	B	Salicylic acid - 30mg/g, Betamethasone (dipropionate) - 0.5mg/g		Ointment	352,087 L.L
L01EA03	TASIGNA	B	Nilotinib - 200mg	200mg	Capsule	412,535,139 L.L
N01AB08	SEVOFLURANE	B	Sevoflurane -		Inhalation	12,327,290 L.L
N03AG01	DEPAKINE	B	Sodium Valproate - 500mg	500mg	Tablet, enteric coated	479,752 L.L
N05AX13	TREVICTA	B	Paliperidone - 350mg	350mg	Injectable suspension, prolonged release	50,113,800 L.L
A07EC02	PENTASA XTEND	B	Mesalazine - 2g	2g	Granules for suspension	8,550,789 L.L
A10BX02	NOVONORM	B	Repaglinide - 2mg	2mg	Tablet	666,546 L.L
C03CA02	BURINEX	B	Bumetanide - 5mg	5mg	Tablet	1,054,916 L.L
N05AX13	TREVICTA	B	Paliperidone - 525mg	525mg	Injectable suspension, prolonged release	75,169,378 L.L
R05DB13	SINECOD	B	Butamirate dihydrogenocitrate - 15mg/10ml	15mg/10ml	Syrup, sugar free	521,411 L.L
A07EC02	ASACOL	B	Mesalazine - 500mg	500mg	Suppository	1,703,992 L.L
C03DA01	ALDACTONE	B	Spironolactone - 100mg	100mg	Tablet	458,250 L.L
L01EA03	TASIGNA	B	Nilotinib - 150mg	150mg	Capsule	323,961,910 L.L
N03AG01	DEPAKINE	B	Sodium Valproate - 200mg	200mg	Tablet, enteric coated	240,548 L.L
N05AX13	BYANNLI	B	Paliperidone - 1000mg	1000mg	Injectable suspension, prolonged release	141,224,257 L.L
A07EC02	SALOFALK 500	B	Mesalazine - 500mg	500mg	Suppository	677,297 L.L
A10BX02	NOVONORM	B	Repaglinide - 0.5mg	0.5mg	Tablet	475,720 L.L

...

190